NCT00730288View on ClinicalTrials.gov

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

January 31, 2008

Conditions
DengueDengue FeverDengue Hemorrhagic FeverDengue Virus
Interventions
BIOLOGICAL

Chimeric dengue serotype (1, 2, 3, 4)

0.5 mL, Subcutaneous, 1 dose

BIOLOGICAL

Chimeric dengue serotype (1, 2, 3, 4)

0.5 mL, Subcutaneous, 1 dose

BIOLOGICAL

Chimeric dengue serotype (1, 2, 3, 4)

0.5mL, Subcutaneous, 1 dose

Trial Locations (1)

Unknown

Adelaide

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00730288 - Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects | Biotech Hunter | Biotech Hunter